Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Feb 23;13(2):e13524.
doi: 10.7759/cureus.13524.

Lymphadenopathy Associated With the COVID-19 Vaccine

Affiliations
Case Reports

Lymphadenopathy Associated With the COVID-19 Vaccine

Nurith Hiller et al. Cureus. .

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has dominated nearly everyone's life since its initial outbreak in the Hubei province of China in December 2019. The disease had spread quickly throughout the world causing extensive, widespread morbidity, over two million deaths, and economical and social devastation over the entire world. Researchers and pharmaceutical companies around the globe have been racing to develop potent and safe vaccines for the disease. Pfizer-BioNTech COVID-19 vaccine followed by Moderna COVID-19 mRNA-1273 vaccine were the first to receive FDA approval. These vaccines are based on messenger RNA novel technology and considered efficient in preventing contagion ensuring safety. Known side effects for this vaccine have been reported as very similar to those known for other vaccines. Specifically, lymphadenopathy has not been considered a common manifestation of COVID-19 vaccination. Israel has been cited as leading in the introduction of these vaccines, which are available for every citizen older than 16 years. Here, we present the cases of three patients who developed lymphadenopathy after the first dose of Pfizer-BioNTech COVID-19 vaccine. Time elapsed from the injection until the appearance of the enlarged nodes, clinical symptoms, and sonographic features differed between the patients, but in all cases gradual regression was noted in the enlarged nodes until complete resolution. Accordingly, to our knowledge, this is the first report describing post-COVID-19 vaccine lymphadenopathy detailing the clinical aspects, sonographic features, and outcomes.

Keywords: covid-19; covid-19 vaccine; regional lymphadenopathy; side effects; ultrasound.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. (a) Focal swelling in the left infraclavicular area that prompted the study (arrow). (b) Ultrasound image of the area demonstrating enlarged lymph nodes with a slightly hypoechoic cortical layer but with preserved hilum and blood supply.
Figure 2
Figure 2. Ultrasound image of the supraclavicular area demonstrating hypoechoic rounded lymph nodes without identifiable hilum and without visible blood flow.
Figure 3
Figure 3. Ultrasound of the left axilla showing enlarged node with normal architecture and blood flow.
Figure 4
Figure 4. Ultrasonographic image demonstrating hypoechoic lymph nodes without blood flow, adjacent to the axillary vein.

References

    1. Messenger RNA-based vaccines against infectious diseases [Online ahead of print] Alameh MG, Weissman D, Pardi N. Curr Top Microbiol Immunol. 2020 - PubMed
    1. mRNA as a transformative technology for vaccine development to control infectious diseases. Maruggi G, Zhang C, Li J, Ulmer JB, Yu D. Mol Ther. 2019;10:757–772. - PMC - PubMed
    1. Advances in mRNA vaccines for infectious diseases. Zhang C, Maruggi G, Shan H, Li J. Front Immunol. 2019;27:594. - PMC - PubMed
    1. Fact sheet for recipients and caregivers: emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) in individuals 16 years of age and older. [Jan;2021 ];https://www.fda.gov/media/144414/download 2020
    1. Defending against smallpox: a focus on vaccines. Voigt EA, Kennedy RB, Poland GA. Expert Rev Vaccines. 2016;15:1197–1211. - PMC - PubMed

Publication types

LinkOut - more resources